Dr. Joe Yeong is a clinician-innovator and immunopathologist focused on overcoming resistance to cancer immunotherapy using advanced technologies and artificial intelligence, with a core vision to bridge immunology and pathology. He is a pioneer in spatial technologies, has translated assays into clinical practice (from bench to bedside), and has published over 150 peer-reviewed papers (Top 2% Scientist), delivering more than 100 invited international talks. His cancer immunology research has been supported by national, international, and industry-sponsored funding exceeding USD 20 million since 2017.

He has served as a committee member of the American Society of Clinical Oncology (ASCO), co-organizer of the World Immunotherapy Council (WIC) and the Society for Immunotherapy of Cancer (SITC), and contributor to multiplex immunofluorescence expert consensus meetings. He is a founding Program Chair of CLINICCAI-MICCAI, a founding board member of MICCAI SIG-ComPath, and a board member of the Asian Society of Digital Pathology. He holds editorial roles with Nature Springer, Journal for ImmunoTherapy of Cancer (JITC), Journal of Clinical Oncology (JCO, ASCO), and World Scientific (Chief Editor).

Dr. Yeong serves as Executive Secretary of the Singapore Society of Oncology–Cancer Immunotherapy Consortium, Co-Lead for Education and Diagnostics at the SingHealth Duke-NUS Cell Therapy Centre, and Advisor for Spatial Technologies at the Cancer Discovery Hub, National Cancer Centre. In 2023, he co-founded the World Immunotherapy Council APAC Chapter to advance tumour immunology and cancer immunotherapy education, research, and collaboration across Asia-Pacific.

He is also a regular grant reviewer for funding agencies in over 15 countries across five continents and for leading journals including Cell, The Lancet, Nature Medicine, and Nature.